The Dutch firm, you see, is like a portly nobleman, resting upon his laurels. Solid, dependable, but lacking the agility of a younger, hungrier contender. We shall examine, therefore, the prospects of Micron Technology and Oracle, two players who, while not yet masters of the realm, possess the potential to become so, and to expose the inherent fragility of any seemingly unassailable dominion.
Navan, for the uninitiated, is a company that manages corporate spending. Essentially, it’s a digital butler for expense reports. It takes the soul-crushing task of reconciling receipts—those flimsy, fading testaments to our fleeting existences—and automates it. A noble pursuit, if you discount the fact that it’s enabling more spending, which, historically, hasn’t ended particularly well. (Though, to be fair, neither has not spending. It’s a conundrum.)
The problem is, everything feels a bit frothy, doesn’t it? Everyone’s throwing money at AI, and I’m starting to suspect a lot of it is just…hope. But Vertiv, they actually do something. They provide the infrastructure. The power, the cooling, the racks…all the boring but essential stuff that keeps the AI humming. Which, again, is good. Less chance of it suddenly deciding it doesn’t like us.
But today’s exuberance isn’t merely a reflection of the market’s fondness for shiny things. No, sir. It’s down to a rather startling discovery concerning the quantity of said shiny things lurking beneath the Nevada dust at Hycroft’s mine. It seems they’ve stumbled upon a positively generous vein, a bit like finding a tenner in an old coat pocket, only considerably more valuable.
The market, quick to scent opportunity, has already offered its benediction. Deere’s shares, ascending with a near 30% climb at the year’s opening, reflect a belief in this metamorphosis. But the seasoned investor, like a cartographer tracing the contours of a shifting landscape, must pause and consider the deeper currents at play.
Right now, NuScale is a money-losing startup in the nuclear power industry, which is… a bold career choice in 2026. They’re trying to land their first sale of a small modular reactor. It’s exciting! It’s also like betting on a horse that hasn’t left the stable yet. Until they actually build something, it’s all just PowerPoint presentations and hopeful engineering. The opportunity size is, shall we say, theoretical.
The filing with the SEC, dated the fourth of February in the year of our Lord two thousand and twenty-six, reveals the entirety of Pacific Ridge’s stake – a sum of seventeen million, one hundred thousand dollars – has been exchanged for more…liquid amusements, no doubt. A rather tidy sum, to be sure, though one diminished by eight million dollars from its prior valuation. A cautionary tale, perhaps, that even the most promising ventures can prove as fleeting as a courtier’s favor.
However, and this is the crucial bit, if one were to cast an eye about for a healthcare stock with the potential to do rather well over the next decade, UnitedHealth, despite its recent wobble, emerges as a prime candidate. A bit like a slightly rumpled but ultimately dependable uncle, wouldn’t you say?
Anyway, two stocks. Two. That’s all I’m focusing on. Because if I look at more than two, I’ll just get overwhelmed and end up buying beanie babies again. It’s happened before. Don’t judge.
My preferred method of tackling this particular conundrum is through an international ETF, a rather clever bit of financial engineering, and the Vanguard Total International Stock ETF (VXUS +0.38%) strikes me as a particularly sound specimen. If you’re contemplating a dabble in the international arena and VXUS has caught your eye, there’s one thing you ought to know, a detail that separates the discerning investor from the merely enthusiastic.